Allurion Technologies price target lowered to $16 on split-adjusted basis

Roth MKM lowered the firm’s price target on Allurion Technologies (ALUR) to $16 from $50 and keeps a Buy rating on the shares. The firm is updating its model to reflect the company’s recent reverse stock split and financings, which should provide enough capital to fund the company into late 2026, the analyst tells investors in a research note. Roth further cites Allurion’s recent positive topline data from their AUDACITY trial that evaluated the safety and efficacy of the ALUR Balloon, noting that the results more than satisfy FDA requirements and set up for the fourth and final module submission for Pre-Market Approval that pave the way for approval in mid-2026 while opening a wider market opportunity.